Data / Form D filings / TelyRx Finco Inc.
TelyRx Finco Inc.: Form D filing
TelyRx Finco Inc., a pharmaceuticals company in Toronto, Ontario, Canada, filed a Form D with the SEC in 2026. The latest, on April 20, 2026, reports $12.6 million sold of a $12.6 million offering to 51 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 333 Bay Street, Suite 2400, Toronto, Ontario, Canada, M5H 2
- Phone
- (800) 878-1660
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Ontario, Canada
- Year incorporated
- 2026
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2125491
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | New notice | $12,623,935 | $12,623,935 | 51 | Mar 26, 2026 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Vanessa Slowey | Director, Executive Officer | |
| John Eric Cascio | Executive Officer, Director |
Every Form D from the week of Apr 20, 2026 · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what TelyRx Finco Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.